

Repel. Eliminate. Protect.


Every year, millions of vascular access patients face preventable complications from Central Line-Associated Bloodstream Infection (CLABSI)Â Â and clotting.
Trinity Vascular Technologies was founded to change that by bringing a clinically proven, patent-protected surface technology to the devices that need it most.

Advancing Infection Prevention in Vascular Access
Trinity Vascular Technologies has developed a differentiated triple-action antimicrobial surface platform for vascular access devices and is advancing toward regulatory clearance and commercialization.
Â
We address one of healthcare’s most persistent and costly challenges: catheter-related bloodstream infections.
The Clinical & Economic Imperative
​

Why Now? Hospitals Bear the Financial Risk
-
~250,000+ CLABSI cases annually in the U.S.
-
$40,000–$75,000+ incremental cost per infection — largely borne by hospitals
-
Increased ICU stays, mortality, and litigation exposure
-
CMS HAC Reduction Program penalizes worst performers by 1% of total Medicare inpatient payments
The Economic Problem
-
Medicare & Medicaid do not reimburse hospital-acquired infection costs
-
The $40,000–$75,000 per case directly impacts hospital margins
-
Poor performance can reduce CMS reimbursement across all admissions (5+ million in annual lost revenue per hospital)
Our Technology Platform
Best-in-class Triple-action Antimicrobial Strategy
Trinity Vascular Technologies developed a scalable triple-action antimicrobial surface platform designed for next-generation vascular access devices, including central venous catheters (CVC).

Bacterial colonies from existing CVC (left) vs. our CVC (right)

Zwitterionic Anti-fouling Surface
Surface chemistries incorporated into FDA-cleared medical devices, reducing microbial adhesion and biofilm formation.
Clinically Established Antimicrobial Agents
Integration of FDA-approved antibiotic combinations with established efficacy in vascular access applications.
Synergistic Dual-Mechanism Design
Combines anti-fouling surface repulsion with localized antimicrobial activity to address both bacterial attachment and colonization.